SAN FRANCISCO--(BUSINESS WIRE)--PicnicHealth, a patient-centered health technology company, today announced the presentation of three abstracts to be presented at ISPOR 2023 from the company’s neurology-focused research programs. The poster presentations leverage previously undisclosed data from cohorts of consented patients with myasthenia gravis, Alzheimer’s Disease, and multiple sclerosis.
“These posters illustrate the utility of PicnicHealth’s patient-centric approach to collecting real-world data and demonstrate the range of research questions that can be answered about patient journeys and factors leading to delays in diagnosis or care,” said Kristen Hahn, PhD, MPH, Head of Real-World Evidence. “We hope that data generated from these and our other neurology-focused research cohorts can ultimately be used to improve care for patients with neurological diseases and support researchers seeking to understand the clinical and economic value of therapies.”
This news comes on the heels of PicnicHealth's recent announcement with Roche and Genentech, where the two parties have agreed to continue their real-world data strategic partnership to advance neurological disease research.
The following abstracts will be presented as poster presentations during ISPOR 2023, May 7-10, 2023, in Boston, Mass.
Poster EPH23: Disease Modifying Therapy (DMT) Utilization and Health Care Resource Utilization (HCRU) Among Adults with Multiple Sclerosis (MS) in a United States-Based Real-World Cohort
Poster Session: Monday, May 8, 2023; 9:45 a.m. – 1:15 p.m. ET
Managing multiple Sclerosis (MS) often requires treatment with specific drugs, known as disease modifying therapies (DMTs), and patients may need to go to the doctor more frequently. Additionally, taking and changing medications and the need for imaging, hospitalizations, and doctor’s visits can be difficult for patients. This research looks at patients’ experiences with DMTs and how patients with MS are using the healthcare system.
Poster HSD54: Utilization of Diagnostic Testing in Alzheimer’s Patients
Poster Session: Tuesday, May 9, 2023; 9:45 a.m. – 1:15 p.m. ET
Cognitive impairment and amyloid plaques are clear hallmarks of Alzheimer's disease and frequently used to inform clinical trial participation and patient treatment plans. This research looks at medical records from 300 patients with a confirmed Alzheimer's diagnosis to examine the utilization of cognitive and biomarker screening tools in the real world, using both the structured and unstructured portions of the medical record. The majority of study participants did not have any evidence of cognitive or biomarker testing, indicating these screens are limited in clinical practice. While previous studies identified a smaller percentage of patients undergoing standard cognitive screening, this sample developed using the addition of unstructured physician notes identifies more measurements than structured data sources alone.
Poster HSD100: Exploring the Path to Diagnosis for Patients with Myasthenia Gravis Using Real-World Data
Poster Session: Wednesday, May 10, 2023; 8:30 – 11:30 a.m. ET
Diagnosing myasthenia gravis (MG) can be a complex process. This research shows that, once patients start to have symptoms, it often takes more than 5 months of doctor visits and testing before they are diagnosed. For patients with less common types of MG, that process can take more than a year. Having symptoms and waiting for a diagnosis can be a stressful time. This research highlights a piece of what that experience looks like for patients with MG across the United States.
PicnicHealth is a healthcare technology company that partners directly with patients to build deep real-world datasets. The company leverages state-of-the-art machine learning, combined with human curation, to port complete medical records into an easy-to-use online application. The platform gives patients unprecedented access to and control over their medical records and, with their consent, the opportunity to contribute this valuable data to further scientific research. Founded in 2014 by Noga Leviner and Troy Astorino, the company partners with dozens of the world’s largest biopharma companies and academic research institutions. Learn more at PicnicHealth.com and picnichealth.com/research-platform.